Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic

Pyxis Oncology is aiming to close out a transformative 2021 with an IPO. Having licensed a pair of antibody-drug conjugates (ADCs) from Pfizer and raised a megaround to develop them, Pyxis is now seeking to tap public investors for cash in an IPO filing that sets the initial fundraising target at $100 million.